信达生物(1801.HK)获纳入恒指成份股及国指成份股，今日股价表现强势，一度涨近5%报91.6港元。各 指数成份股变动将于12月5日(星期五)收市后实施，并于12月8日(星期一)起生效。 ...

Core Insights - The Hong Kong stock market opened positively on November 24, with the Hang Seng Index rising by 0.92%, the Hang Seng Tech Index by 1.13%, and the Hang Seng China Enterprises Index by 0.81% [1] - Notable sectors included technology stocks, gold stocks, innovative drug concepts, lithium battery stocks, and automotive stocks, indicating active market participation and strong capital interest [1] - The inclusion of Innovent Biologics, a significant biotech company, into the Hang Seng Index reflects the growing recognition and importance of quality Chinese innovative drug companies in the mainstream capital market [1] Market Performance - The Hang Seng Index and related ETFs, such as the Hang Seng ETF (159920) and Hang Seng China Enterprises ETF (159850), experienced a strong opening and continued to rise throughout the trading session [1] - The market showed active trading with significant attention from investors, highlighting a positive sentiment towards the Hong Kong stock market [1] Company Developments - Innovent Biologics has become the fourth innovative drug company to be included in the Hang Seng Index, joining other companies that have transitioned from traditional pharmaceuticals to innovative drug enterprises [1] - This inclusion signifies a benchmark status for Innovent Biologics and underscores the increasing focus on high-quality Chinese biotech firms in the international market [1]

每经AI快讯，信达生物(01801.HK)一度涨近5%，截至发稿，涨3.9%，报90.65港元，成交额1.77亿港 元。 ...

消息面上，11月21日，恒生指数系列季度检讨结果出炉，所有变动将于2025年12月8日起生效。其中， 信达生物将被纳入恒生指数成份股，成份股数目将由88只增加至89只。 信达生物(01801)一度涨近5%，截至发稿，涨3.9%，报90.65港元，成交额1.77亿港元。 值得一提的是，11月20日，信达生物宣布，玛仕度肽注射液(胰高血糖素[GCG]/胰高血糖素样肽-1[GLP- 1]双受体激动剂，研发代号：IBI362)在中国中重度肥胖人群中开展的III期临床研究(GLORY-2)达成主要 终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg用于成人体重控制的新药上 市申请。 ...

智通财经APP获悉，信达生物(01801)一度涨近5%，截至发稿，涨3.9%，报90.65港元，成交额1.77亿港 元。 消息面上，11月21日，恒生指数系列季度检讨结果出炉，所有变动将于2025年12月8日起生效。其中， 信达生物将被纳入恒生指数成份股，成份股数目将由 88 只增加至 89 只。 值得一提的是，11月20日，信达生物宣布，玛仕度肽注射液（胰高血糖素[GCG] /胰高血糖素样 肽-1[GLP-1] 双受体激动剂，研发代号：IBI362）在中国中重度肥胖人群中开展的III期临床研究 （GLORY-2）达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg用于 成人体重控制的新药上市申请。 ...

Group 1 - The core point of the article is the inclusion of Innovent Biologics in the Hang Seng ESG Enhanced Index as part of the quarterly index review by Hang Seng Indexes Company [1] Group 2 - The announcement was made on November 21, indicating a significant update in the ESG index landscape [1] - The review also included the Hang Seng ESG Enhanced Select Index and the Hang Seng China Enterprises ESG Enhanced Index, highlighting a broader focus on ESG criteria [1]

Group 1 - Hang Seng Index will include Innovent Biologics (01801), increasing the number of constituent stocks from 88 to 89 [1][4] - Hang Seng China Enterprises Index will include China Hongqiao (01378), Innovent Biologics, and Yum China (09987), while New Energy (02688) and New Oriental-S (09901) will be removed, maintaining a total of 50 constituent stocks [3][5] - Hang Seng Technology Index will include Leapmotor (09863), while ASMPT (00522) will be removed, keeping the number of constituent stocks at 30 [7][9] Group 2 - Hang Seng Composite Index will include FWD Group (01828), Hesai Technology-W (02525), Aux Group (02580), Geekplus Technology-W (02590), Yino Pharma (02591), and Chery Automobile (09973), increasing the number of constituent stocks from 503 to 509 [10][11][12]

Group 1: Hang Seng Index - Xinda Biopharmaceutical (01801) will be included in the Hang Seng Index constituent stocks, increasing the number of constituents from 88 to 89 [1][2]. Group 2: Hang Seng China Enterprises Index - China Hongqiao (01378), Xinda Biopharmaceutical (01801), and Yum China (09987) will be added to the Hang Seng China Enterprises Index, while New Energy (02688) and New Oriental Education (09901) will be removed, maintaining a total of 50 constituents [4][5]. Group 3: Hang Seng Technology Index - Leapmotor (09863) will be included in the Hang Seng Technology Index, while ASMPT (00522) will be removed, keeping the number of constituents at 30 [7][8]. Group 4: Hang Seng Composite Index - FWD Group (01828), Hesai Technology (02525), Aux Group (02580), DeepGlint (02590), Yino Pharma (02591), and Chery Automobile (09973) will be added to the Hang Seng Composite Index, increasing the number of constituents from 503 to 509 [10][11].

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

Group 1 - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] - Innovent Biologics announced that its drug IBI362 has achieved primary and all key secondary endpoints in a Phase III clinical trial for obesity, with plans to submit a new drug application for weight control [1] - The drug IBI362 is a dual receptor agonist for glucagon and GLP-1, and is the first of its kind approved globally for obesity and type 2 diabetes management [1] Group 2 - Junshi Biosciences' PD-1 inhibitor, H drug, has been officially included in the breakthrough therapy list by the NMPA for use in perioperative treatment of gastric cancer, marking a significant recognition of its clinical value [2] - This breakthrough designation is expected to accelerate the review and approval process for H drug, filling a gap in immune therapy for gastric cancer [2] - The approval of PB-119 by the NMPA highlights the competitive advantage of the drug based on solid clinical data and innovative PEGylation technology, which balances efficacy and reduces side effects [1][3] Group 3 - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs [3] - The National Healthcare Security Administration is encouraging the high-quality development of innovative drugs, indicating a warming trend in payment policies for innovative drugs [3] - Domestic pharmaceutical companies are actively transitioning towards innovation, supported by ongoing reforms in drug approval processes [3] Group 4 - Relevant Hong Kong stocks in the innovative drug sector include Heng Rui Medicine, Kelun-Botai Biopharmaceutical, and others, indicating a growing interest in the market [4]